title: [Mesenteric traction syndrome].
abstract: Mesenteric traction syndrome (MTS) manifests in 58-87% of patients undergoing upper abdominal surgery and is characterised by a triad of hypotension, tachycardia, and flushing. Prostacyclin is released from the gut mucosa following intestinal eventration and cyclooxygenase antagonists prevent the development of MTS. Also the use of remifentanil appears to increase the incidence of MTS and hypotension is aggravated by epidural analgesia. Yet, prostacyclin may be important for maintaining microcirculation within the splanchnic area and preserve its mucosal barrier.
authors.affiliation: Kirurgisk gastroenterologisk klinik C-Tx, Rigshospitalet 2122, Blegdamsvej 9, 2100 København Ø. paulskrohn@dadlnet.dk.
authors.forename: Paul Suno
authors.initials: PS
authors.lastname: Krohn
authors.forename: Rikard
authors.initials: R
authors.lastname: Ambrus
authors.forename: Morten
authors.initials: M
authors.lastname: Zaar
authors.forename: Niels H
authors.initials: NH
authors.lastname: Secher
authors.forename: Lars Bo
authors.initials: LB
authors.lastname: Svendsen
mesh_terms: D000005:Abdomen / Q000601:surgery; D016861:Cyclooxygenase Inhibitors / Q000627:therapeutic use; D011464:Epoprostenol / Q000097:blood; D005483:Flushing / Q000188:drug therapy / Q000503:physiopathology*; D006801:Humans; D007022:Hypotension / Q000188:drug therapy / Q000503:physiopathology*; D007431:Intraoperative Complications / Q000503:physiopathology; D013152:Splanchnic Circulation / Q000187:drug effects; D013577:Syndrome; D013610:Tachycardia / Q000188:drug therapy / Q000503:physiopathology*
chemical_list: D016861:Cyclooxygenase Inhibitors; D011464:Epoprostenol